{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:12:13Z","timestamp":1783998733810,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.tmrv.2025.150896","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T20:00:24Z","timestamp":1744056024000},"page":"150896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["ADAMTS13 Testing During Clinical Remission of Immune Thrombotic Thrombocytopenic Purpura: A Critical Review"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0384-704X","authenticated-orcid":false,"given":"Danielle H.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maple","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diva","family":"Baggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles","family":"Kelsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbey","family":"Willcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Htun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda K.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.tmrv.2025.150896_bib0001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/ijlh.13557","article-title":"ADAMTS13 testing update: focus on laboratory aspects of difficult thrombotic thrombocytopenic purpura diagnoses and effects of new therapies","volume":"43","author":"Smock","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"10","key":"10.1016\/j.tmrv.2025.150896_bib0002","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"14","key":"10.1016\/j.tmrv.2025.150896_bib0003","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.tmrv.2025.150896_bib0004","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.tmrv.2025.150896_bib0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.tmrv.2025.150896_bib0006","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura","volume":"130","author":"Sadler","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.tmrv.2025.150896_bib0007","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.tmrv.2019.06.005","article-title":"Taking empiricism out of immune thrombotic thrombocytopenic purpura: current and future treatment strategies","volume":"33","author":"Mazepa","year":"2019","journal-title":"Transfus Med Rev"},{"issue":"5","key":"10.1016\/j.tmrv.2025.150896_bib0008","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2141.2008.07107.x","article-title":"Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse","volume":"141","author":"Jin","year":"2008","journal-title":"British journal of haematology"},{"issue":"8","key":"10.1016\/j.tmrv.2025.150896_bib0009","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.tmrv.2025.150896_bib0010","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood-2006-02-006064","article-title":"Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity","volume":"109","author":"Ferrari","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.tmrv.2025.150896_bib0011","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"20","key":"10.1016\/j.tmrv.2025.150896_bib0012","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.tmrv.2025.150896_bib0013","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2016-06-724161","article-title":"Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura","volume":"128","author":"Page","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.tmrv.2025.150896_bib0014","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.tmrv.2025.150896_bib0015","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission","volume":"93","author":"Peyvandi","year":"2008","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.tmrv.2025.150896_bib0016","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1538-7836.2009.03433.x","article-title":"The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission","volume":"7","author":"Groot","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.tmrv.2025.150896_bib0017","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1538-7836.2012.04808.x","article-title":"ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura","volume":"10","author":"Bettoni","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1016\/j.tmrv.2025.150896_bib0018","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood.2022016640","article-title":"Race, rituximab, and relapse in TTP","volume":"140","author":"Chaturvedi","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.tmrv.2025.150896_bib0019","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1538-7836.2006.01758.x","article-title":"A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption\/ionization time-of-flight (SELDI-TOF)-mass spectrometry","volume":"4","author":"Jin","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"9","key":"10.1016\/j.tmrv.2025.150896_bib0020","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood-2003-05-1616","article-title":"Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura","volume":"102","author":"Scheiflinger","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.tmrv.2025.150896_bib0021","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/01.moh.0000169286.74464.3a","article-title":"Measurement of ADAMTS13 activity and inhibitors","volume":"12","author":"Miyata","year":"2005","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"10.1016\/j.tmrv.2025.150896_bib0022","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2141.2004.05217.x","article-title":"von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura","volume":"127","author":"Peyvandi","year":"2004","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.tmrv.2025.150896_bib0023","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/ajh.25845","article-title":"Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study","volume":"95","author":"Schieppati","year":"2020","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.tmrv.2025.150896_bib0024","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/17474086.2021.2003703","article-title":"Predictors of relapse and preventative strategies in immune thrombotic thrombocytopenic purpura","volume":"14","author":"Pavenski","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1016\/j.tmrv.2025.150896_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100108","article-title":"ADAMTS13 activity testing: evaluation of commercial platforms for diagnosis and monitoring of thrombotic thrombocytopenic purpura","volume":"7","author":"Singh","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"Supplement 1","key":"10.1016\/j.tmrv.2025.150896_bib0026","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1182\/blood-2021-150594","article-title":"Real-world variability in ADAMTS13 assay methods may impact upon follow up for patients with thrombotic thrombocytopenic purpura (TTP)","volume":"138","author":"Ling","year":"2021","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.tmrv.2025.150896_bib0027","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/bloodadvances.2017008268","article-title":"Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens","volume":"1","author":"Westwood","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.tmrv.2025.150896_bib0028","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221112217","article-title":"Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase","volume":"13","author":"Westwood","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"11","key":"10.1016\/j.tmrv.2025.150896_bib0029","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1111\/trf.13751","article-title":"Idiopathic thrombotic thrombocytopenic purpura: strongest risk factor for relapse from remission is having had a relapse","volume":"56","author":"Mai Falk","year":"2016","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.tmrv.2025.150896_bib0030","first-page":"369","article-title":"Rituximab in the treatment of immune-mediated thrombotic thrombocytopenic purpura","volume":"21","author":"\u00d6zpolat","year":"2023","journal-title":"Blood Transfus"},{"issue":"10","key":"10.1016\/j.tmrv.2025.150896_bib0031","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura","volume":"125","author":"Lim","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.tmrv.2025.150896_bib0032","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/bloodadvances.2019031039","article-title":"Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura","volume":"3","author":"Sun","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.tmrv.2025.150896_bib0033","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2014-02-553131","article-title":"Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes","volume":"124","author":"Scully","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.tmrv.2025.150896_bib0034","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/jth.13922","article-title":"An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura","volume":"16","author":"Roose","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.tmrv.2025.150896_bib0035","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jtha.2023.10.014","article-title":"Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura","volume":"22","author":"De Waele","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"25","key":"10.1016\/j.tmrv.2025.150896_bib0036","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood.2023023269","article-title":"Peak ADAMTS13 activity to assess ADAMTS13 conformation and risk of relapse in immune-mediated thrombotic thrombocytopenic Purpura","volume":"143","author":"Prasannan","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.tmrv.2025.150896_bib0037","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3390\/math12050631","article-title":"Novel design and analysis for rare disease drug development","volume":"12","author":"Chow","year":"2024","journal-title":"Mathematics"},{"issue":"26","key":"10.1016\/j.tmrv.2025.150896_bib0038","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1002\/sim.7900","article-title":"A bayesian analysis of small n sequential multiple assignment randomized trials (snSMARTs)","volume":"37","author":"Wei","year":"2018","journal-title":"Stat Med"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796325000227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796325000227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T15:54:31Z","timestamp":1747842871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796325000227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0887796325000227"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2025.150896","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ADAMTS13 Testing During Clinical Remission of Immune Thrombotic Thrombocytopenic Purpura: A Critical Review","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2025.150896","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150896"}}